Address Hotels and Resorts Announces the Opening of Address Jabal Omar Makkah Unveiling a Spiritual Haven in the Heart of Makkah
12.7.2023 09:00:00 EEST | Business Wire | Press release
Address Hotels and Resorts is thrilled to announce the opening of its latest architectural and hospitality masterpiece, Address Jabal Omar Makkah, in the holy city of Makkah, Saudi Arabia. Nestled in the iconic Jabal Omar development, this landmark property offers a truly unforgettable experience for pilgrims and travellers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711493267/en/
Panoramic Kaaba view from Address Jabal Omar Makkah (Photo: AETOSWire)
The largest hotel within the Address Hotels and Resorts portfolio, Address Jabal Omar Makkah boasts an impressive 1,484 rooms and suites. With its striking architectural design, a seamless fusion of ancient Arabian charm and contemporary opulence, the hotel is the tallest building in Jabal Omar and is a breathtaking sight.
One standout feature of Address Jabal Omar Makkah is its proximity to the sacred Holy Kaaba and Al Masjid Al Haram, along with the Makkah Museum, Masjid Al Jinn, Jannat al-Mu'alla Cemetery, and the iconic Abraj Al Bait Towers. Designed by the world-renowned architects Foster & Partners, the towers of Address Jabal Omar Makkah span over 5,000 sqm and the development includes a commercial area featuring a diverse range of shops, showcasing local, regional, and international brands.
Address Jabal Omar Makkah offers a range of exquisitely designed accommodations to suit every traveller’s needs. From luxurious Deluxe Rooms, which provide splendid views of the Holy Kaaba or the Holy City, to indulgent Suites and the magnificent three-bedroom Presidential Suite and four-bedroom Penthouse, guests can immerse themselves in comfort and elegance.
With four restaurants, two lobby lounges, and two club lounges, guests can also savour a wide range of delectable cuisines. The hotel's signature dining venue offers traditional Hejazi cuisine and other Saudi Arabian specialties, where live cooking stations showcase international flavours alongside time-honoured delicacies.
The spa and wellness offerings, including the first-ever Foot Spa by Address Hotels and Resorts, at the hotel are designed to provide guests with a truly holistic experience. With a complimentary Fitness Centre, equipped with the latest Technogym equipment on hand as well, guests can maintain their well-being during their stay.
Address Jabal Omar Makkah is also a premier destination for conferences and events. Whatever the occasion, the hotel’s unparalleled settings and services help create cherished moments. The property's multifunctional meeting spaces are designed to cater to events of any scale. The hotel's creative chefs curate menus tailored to individual preferences, ensuring a flawless and memorable event.
Mark Kirby, Head of Emaar Hospitality, said, “We are delighted to announce the opening of Address Jabal Omar Makkah. Its prime location makes it the preferred choice for those seeking to deepen their spiritual connection. With spacious rooms and suites, multiple dining options, and state-of-the-art prayer facilities, the hotel offers all the amenities necessary for a meaningful and unforgettable pilgrimage experience. Whether guests are here for Hajj, Umrah, or to enhance their spiritual connection, Address Jabal Omar Makkah Hotel is the optimal starting point for their journey.”
The hotel is proud to be a part of Saudi Arabia's Vision 2030, which aims to transform the country's tourism landscape.
To reserve with a 15% discount, click the link, visit our website, or email stayatmakkah@addresshotels.com or call +966-0125531444.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711493267/en/
Contact information
Mohammad Jamil
Mohammad.j@addresshotels.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom